Why It Matters

Amgen Inc., one of the world's largest biotechnology companies, has terminated its lobbying relationship with Washington Advocacy Group, according to a lobbying disclosure filed on June 12, marking the end of an engagement that focused on healthcare regulations and congressional outreach.

The filing shows a $5,000 termination amount, a standard administrative fee for ending a lobbying relationship. Michael Lamoureux, a partner at Washington Advocacy Group, served as the lead lobbyist on the Amgen account, handling monitoring of healthcare regulations and statutes while educating members of Congress on related issues.

Amgen had a trailing twelve-month revenue of approximately $37.2 billion as of the first quarter of 2026. Amgen's product portfolio spans cardiovascular disease, osteoporosis, inflammation and immunology, oncology and hematology, and rare diseases, with blockbuster drugs including Repatha, Prolia, EVENITY, ENBREL, Otezla, TEZSPIRE, BLINCYTO, KYPROLIS, Vectibix, IMDELLTRA, Tepezza, and Krystexxa.

The company's federal footprint extends beyond product advocacy. Amgen holds contracts with the U.S. federal government, including awards from the Department of Health and Human Services. Amgen USA Inc., a subsidiary, also maintains federal contracts.

The pharmaceutical giant faces regulatory pressures on multiple fronts. Amgen has multiple blockbuster drugs subject to or approaching negotiations with the Centers for Medicare and Medicaid Services (CMS) under the Inflation Reduction Act. The company also operates as both a maker of branded biologics and a manufacturer through its Amgen Biosimilars division, requiring it to navigate complex FDA approval pathways and reimbursement parity issues. Additionally, Amgen monitors patent and exclusivity protections as a major pharmaceutical innovator.

Broader Context

Amgen operates in a healthcare policy environment marked by significant congressional activity on drug pricing, biosimilar competition, and pharmaceutical innovation. The company's engagement with the Biomedical Advanced Research and Development Authority (BARDA) and other federal health security programs reflects its role in national preparedness initiatives. The Inflation Reduction Act has reshaped pharmaceutical lobbying priorities across the industry, with companies adjusting strategies around CMS drug price negotiations.

In recent years, Amgen has navigated major corporate challenges that required government engagement. The company acquired Horizon Therapeutics for $27.8 billion in 2023 and 2024, a transaction that drew FTC scrutiny. Amgen subsequently settled FTC challenges related to the Horizon acquisition.

Amgen's clinical pipeline remains robust, with 17 Phase III clinical programs, 8 Phase II programs, and 19 Phase I programs underway as of the termination date. The company is also developing MariTide, an anti-obesity medication, positioning it in a competitive space where regulatory and reimbursement pathways remain unsettled.

The Bottom Line

For a company of Amgen's size and complexity, with substantial federal contracts, significant CMS negotiation exposure, and an active clinical pipeline, healthcare advocacy remains a core function. With blockbuster drugs navigating CMS negotiations, a biosimilar division competing on reimbursement parity, and federal contracts spanning drug supply and preparedness programs, the company's need for experienced healthcare advocacy remains constant.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article